Core Viewpoint - The company is engaged in the research, production, sales, and service of medical device products, focusing on life information and support as well as nephrology medical sectors, with an expected net loss but a narrowing of losses compared to the previous year [5] Group 1: Financial Performance - The company anticipates a continued net loss during the reporting period, although the loss margin is expected to be smaller than the same period last year [5] - Revenue is projected to show slight growth, driven by enhanced management and operational efficiency [5] - The primary reason for the inability to achieve profitability is a decline in sales prices due to market competition, coupled with rising raw material costs, leading to a decrease in overall gross margin [5] Group 2: Cost Management and Impacts - The company is actively pursuing cost control and efficiency improvements, resulting in a year-on-year reduction in various expenses [5] - However, foreign exchange losses due to the depreciation of the US dollar against the Chinese yuan and high amortization costs related to convertible bonds significantly impact net profit [5] - The company has made provisions for asset impairment on inventory and certain production equipment based on prudence principles, which will affect the current net profit [5] Group 3: Future Projections - For 2025, the expected impact of non-recurring gains and losses on net profit is approximately 8.07 million yuan, primarily from government subsidies [5]